CINGW — Cingulate Inc.

CINGWCingulate Inc.

NAS · US · Health Care · Biotechnology · cingulate.com

0.0180USD-70.05%Mkt Cap: —P/E: —Last update: 2026-05-26

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United Sta…

Industry Peers

Biotechnology

VRTX

Vertex Pharmaceuticals Incorporated

Regeneron Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

39.41BUSDP/E 74.0

RVMD

Revolution Medicines, Inc.

Indicators:|

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)—

Gross Profit-9.77M USD

Net Income (TTM)-22.45M USD

Revenue/Share—

Last Price0.0180 USD

Fiscal Year End—

MR Quarter—

Employees14

CountryUS

SectorHealth Care

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B0.02

EPS (TTM)-1.73

EPS (Forward)—

52W Range

0.01614% of range0.0601

52W High0.0601 USD

52W Low0.0161 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-894.81%

ROA-148.94%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-17.25M USD

CapEx (TTM)162.14K USD

FCF Margin—

FCF Yield—

Net Debt-18.46M USD

Net Debt/EBITDA0.78

Balance Sheet

Debt/Equity3.50

Current Ratio2.55

Quick Ratio2.37

Book Value/Sh1.584 USD

Cash/Share1.950 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float12.91M

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta—

S&P 52W Chg28.31%

Avg Vol (30d)3.31K

Avg Vol (10d)—

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—